Blood-Brain Barrier and Neuroimmune Interface in CBS/PSP

Blood-Brain Barrier and Neuroimmune Interface in CBS/PSP

Introduction

The blood-brain barrier (BBB) and neuroimmune interface represent interconnected systems whose dysfunction critically contributes to the pathogenesis of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies share common features of tau protein accumulation, but exhibit distinct patterns of BBB disruption and neuroimmune activation that correlate with their unique clinical phenotypes. Understanding the crosstalk between vascular dysfunction and immune responses provides critical insights into disease mechanisms and therapeutic targeting opportunities.

In CBS and PSP, the BBB undergoes progressive dysfunction that enables peripheral immune cell infiltration, compromises clearance of toxic proteins, and establishes a chronic neuroinflammatory milieu.[@van2025] Simultaneously, microglia and astrocytes adopt reactive phenotypes that further degrade vascular integrity, creating a feed-forward loop between neuroinflammation and vascular dysfunction. This page synthesizes current understanding of these interconnected pathways and their therapeutic implications for 4R-tauopathies.

Neurovascular Unit Architecture in 4R-Tauopathies

Components of the Neurovascular Unit

The neurovascular unit (NVU) comprises multiple cell types that collectively maintain brain homeostasis:

Blood-Brain Barrier and Neuroimmune Interface in CBS/PSP

Introduction

The blood-brain barrier (BBB) and neuroimmune interface represent interconnected systems whose dysfunction critically contributes to the pathogenesis of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies share common features of tau protein accumulation, but exhibit distinct patterns of BBB disruption and neuroimmune activation that correlate with their unique clinical phenotypes. Understanding the crosstalk between vascular dysfunction and immune responses provides critical insights into disease mechanisms and therapeutic targeting opportunities.

In CBS and PSP, the BBB undergoes progressive dysfunction that enables peripheral immune cell infiltration, compromises clearance of toxic proteins, and establishes a chronic neuroinflammatory milieu.[@van2025] Simultaneously, microglia and astrocytes adopt reactive phenotypes that further degrade vascular integrity, creating a feed-forward loop between neuroinflammation and vascular dysfunction. This page synthesizes current understanding of these interconnected pathways and their therapeutic implications for 4R-tauopathies.

Neurovascular Unit Architecture in 4R-Tauopathies

Components of the Neurovascular Unit

The neurovascular unit (NVU) comprises multiple cell types that collectively maintain brain homeostasis:

• Endothelial cells: Form the physical barrier with tight junctions (claudin-5, occludin, ZO-1)
• Pericytes: Cover 80-90% of capillary surface area, regulating cerebral blood flow and BBB integrity
• Astrocyte end-feet: Ensheath blood vessels, releasing factors that maintain barrier function
• Basement membrane: Extracellular matrix (laminin, collagen IV, fibronectin) supporting cellular components
• Neurons: Provide regulatory signals through neurovascular coupling

CBS/PSP-Specific Changes

In 4R-tauopathies, the NVU undergoes characteristic changes:

| Component | PSP Changes | CBS Changes | Functional Impact |
|-----------|-------------|-------------|------------------|
| Endothelial cells | Tau accumulation in endothelial cytoplasm | Asymmetric involvement | Reduced tight junction integrity |
| Pericytes | 30-40% coverage reduction | Variable loss | Impaired capillary regulation |
| Astrocyte end-feet | Tufted astrocyte formation | Reactive astrocytosis | Disrupted BBB maintenance |
| Tight junctions | Claudin-5 downregulation | Regional specificity | Increased paracellular leak |

Evidence from dynamic contrast-enhanced MRI (DCE-MRI) studies demonstrates increased BBB permeability in PSP patients, particularly in the basal ganglia and brainstem regions that show the highest tau pathology burden[@van2025]

Mechanisms of BBB Dysfunction in CBS/PSP

Tau Pathology-Mediated Endothelial Injury

Pathological tau accumulates in brain endothelial cells in 4R-tauopathies, directly compromising barrier function:

Pericyte Dysfunction

Pericytes are particularly vulnerable in PSP and CBS:

• PDGFRβ signaling impairment: Tau affects PDGFRβ phosphorylation critical for pericyte survival
• Coverage reduction: Postmortem studies show 30-40% pericyte loss in PSP basal ganglia[@van2025]
• Contractile dysfunction: Pericytes lose ability to regulate capillary diameter
• Barrier maintenance failure: Reduced pericyte coverage correlates with tight junction loss

Astrocyte End-Foot Damage

Astrocyte pathology in PSP directly impacts BBB integrity:

• Tufted astrocytes: PSP hallmark lesions disrupt normal end-foot ensheathment
• AQP4 mislocalization: Aquaporin-4 polarization is lost, impairing glymphatic clearance
• VEGF dysregulation: Abnormal VEGF release affects endothelial permeability
• Glutamate transporter loss: Impaired glutamate uptake contributes to excitotoxicity

Neuroimmune Activation Patterns

Microglial Phenotypes in 4R-Tauopathies

Microglial activation in CBS and PSP follows distinct patterns from Alzheimer's disease:

PSP Microglia:

• Predominant M1-like pro-inflammatory phenotype
• Highest activation in globus pallidus and subthalamic nucleus
• Strong correlation with regional tau burden
• Elevated TSPO-PET binding

• Mixed M1/M2 phenotype
• Asymmetric activation pattern (contralateral to affected side)
• Higher cortical involvement than PSP
• Variable correlation with tau distribution

TREM2 Dysfunction

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) plays a crucial role in microglial responses to tau pathology:

| TREM2 Function | PSP/CBS Relevance | Therapeutic Target |
|----------------|-------------------|-------------------|
| Lipid sensing | Tau aggregates have lipid components | TREM2 agonists |
| Phagocytosis | Impaired clearance of tau debris | Enhance activation |
| DAM phenotype | Reduced disease-associated microglia | Metabolic support |
| Cytokine production | Elevated IL-1β, IL-6, TNF-α | NLRP3 inhibitors |

Genetic studies show TREM2 variants associate with PSP risk, though the effect is weaker than in Alzheimer's disease. This suggests TREM2 dysfunction contributes to, but is not the primary driver of, 4R-tauopathy pathogenesis.

NLRP3 Inflammasome Activation

The NLRP3 inflammasome is activated in tauopathies, driving production of pro-inflammatory cytokines:

Activation triggers:

• Tau oligomers and fibrils
• Mitochondrial ROS from neuronal dysfunction
• ATP release from damaged neurons
• Amyloid-beta co-pathology (in some cases)

• IL-1β maturation and release
• IL-18 release
• Pyroptosis induction
• Propagation of tau pathology

Crosstalk Between BBB and Neuroimmune Systems

Pericyte-Microglia Communication

A novel axis of crosstalk involves direct communication between pericytes and microglia:

This creates a vicious cycle where pericyte loss leads to microglial activation, which then accelerates pericyte and endothelial damage.

Cytokine-Mediated BBB Disruption

Pro-inflammatory cytokines directly compromise BBB integrity:

| Cytokine | BBB Effect | Source |
|----------|------------|--------|
| TNF-α | Tight junction degradation | Microglia, astrocytes |
| IL-1β | Upregulates adhesion molecules | Activated microglia |
| IL-6 | Increases permeability | Various cell types |
| IFN-γ | Disrupts tight junctions | T-cells (if infiltrating) |

Peripheral Immune Cell Infiltration

BBB breakdown enables peripheral immune cell entry:

• T-cell infiltration: CD4+ and CD8+ T-cells detected in PSP brain tissue
• Monocyte entry: Peripheral monocytes differentiate into brain macrophages
• B-cell presence: Rare, but some evidence of localized B-cell clusters
• Neutrophil involvement: Variable, more prominent in acute injury

Complement System in CBS/PSP

The complement system mediates synaptic elimination and inflammatory responses in 4R-tauopathies:

C1q-Mediated Synapse Tagging

• C1q binds to synapses in an activity-dependent manner
• In tauopathies, excessive C1q deposition occurs
• Tags synapses for microglial elimination via CR3
• Contributes to early synaptic loss before symptom onset

C3/C3R Signaling

• Astrocytes and microglia produce C3
• C3a anaphylatoxin recruits microglia to damaged regions
• C3b opsonizes targets for phagocytosis
• Elevated CSF C3 in PSP patients

Therapeutic Targeting

| Target | Agent | Status | Mechanism |
|--------|-------|--------|-----------|
| C1q | ANX005 | Phase 3 | Antibody inhibition |
| C3 | Pegcetacoplan | Approved (PNH) | C3 inhibitor |
| CR3 | Small molecule antagonists | Preclinical | Block phagocytosis |

Distinct CBS versus PSP Neuroimmune Signatures

Comparative studies reveal disease-specific cytokine profiles:

PSP-Specific Features

• Elevated TNF-α in basal ganglia
• High IL-6 in brainstem regions
• Prominent microglial activation in globus pallidus
• Strong complement activation

CBS-Specific Features

• More asymmetric cytokine distribution
• Higher cortical IL-1β
• Mixed microglial phenotypes
• Greater involvement of peripheral immune markers

Therapeutic Strategies

BBB-Targeting Approaches

Focused Ultrasound

Focused ultrasound (FUS) with microbubbles temporarily disrupts the BBB for enhanced drug delivery:

• Mechanism: Acoustic cavitation causes temporary tight junction opening
• Tau antibody delivery: 3-4 fold increase in brain antibody concentrations
• Safety: BBB restores within 24-48 hours
• Clinical trials: Ongoing for AD, with implications for 4R-tauopathies

Receptor-Mediated Transcytosis

Receptor-mediated transcytosis exploits endogenous transport systems:

| Receptor | Ligand | Therapeutic Application | Status |
|----------|--------|------------------------|--------|
| Transferrin receptor | Transferrin | Antibody delivery | Clinical trials |
| Insulin receptor | Insulin | Peptide delivery | Preclinical |
| LDL receptor | Apolipoprotein E | LNP targeting | Research |
| LRP1 | Various | Peptide conjugates | Research |

Pericyte Stabilization

• PDGF-BB: Promotes pericyte recruitment
• BMP4: Induces pericyte differentiation
• Angiopoietin-1: Stabilizes pericyte-endothelial interactions

Neuroimmune-Targeting Approaches

TREM2 Modulation

• AL002: TREM2 agonist in Phase 2 for AD
• AL003: TREM2 agonist in Phase 1
• DNL311: Brain-penetrant TREM2 bispecific (preclinical)

NLRP3 Inhibition

• Dapansutrile: NLRP3 inhibitor, Phase 2 for inflammatory conditions
• MCC940: High-potency NLRP3 inhibitor (preclinical)
• Colchicine: Microtubule inhibition, trials in AD

Complement Inhibition

• ANX005: C1q antibody, Phase 3 for other indications
• Pegcetacoplan: C3 inhibitor, approved for PNH
• VIB7710: C1q nanobody, Phase 1

Integrated Therapeutic Approach

Given the crosstalk between BBB dysfunction and neuroimmune activation, combination approaches may be most effective:

| Strategy | Target | Rationale |
|----------|--------|-----------|
| FUS + immunotherapy | BBB + tau pathology | Enhanced antibody brain penetration |
| Pericyte stabilization + TREM2 agonist | NVU + microglia | Address both compartments |
| NLRP3 inhibitor + BBB modulator | Neuroinflammation + permeability | Break vicious cycle |
| Complement inhibition + neurotrophins | Synaptic protection + repair | Preserve remaining neurons |

Biomarkers for Patient Stratification

BBB Integrity Markers

| Biomarker | Source | Interpretation |
|-----------|--------|----------------|
| CSF/serum albumin ratio | CSF, blood | Elevated indicates BBB leak |
| sPDGFR-β | Blood | Pericyte injury marker |
| MMP-9 | CSF | Tight junction degradation |
| Claudin-5 | CSF | Tight junction protein loss |

Neuroimmune Activation Markers

| Biomarker | Source | Disease Correlation |
|-----------|--------|-------------------|
| YKL-40 | CSF | Astrocyte activation |
| sTREM2 | CSF | Microglial activation |
| IL-1β | CSF | Inflammasome activity |
| GFAP | Blood | Astrocyte reactivity |

Cross-Links

• [Blood-Brain Barrier Dysfunction Pathway](/mechanisms/bbb-dysfunction-pathway)
• [Neuroimmune Interface Pathway](/mechanisms/neuroimmune-interface)
• [Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp)
• [CBS Neuroinflammation](/mechanisms/cbs-neuroinflammation)
• [BBB Therapeutic Delivery CBS/PSP](/mechanisms/bbb-therapeutic-delivery-cbs-psp)
• [PSP Pathway](/mechanisms/psp-pathway)
• [Corticobasal Syndrome Pathway](/mechanisms/cbs-pathway)
• [TREM2 Therapeutics](/therapeutics/trem2-therapeutics)
• [Personalized Treatment Plan - Atypical Parkinsonism](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)

References